David Scott Miller


AuthID: R-00K-250

Confirmed Publications: 293



181
TITLE: Chemo- and radiotherapy in adjuvant management of optimally debulked endometrial cancer
AUTHORS: David Scott Miller ; Gini Fleming; Marcus E Randall;
PUBLISHED: 2009, SOURCE: JNCCN Journal of the National Comprehensive Cancer Network, VOLUME: 7, ISSUE: 5
INDEXED IN: Scopus CrossRef: 4
IN MY: ORCID
182
TITLE: Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer
AUTHORS: Yi Wen Huang; Joseph C Liu; Daniel E Deatherage; Jingqin Luo; David G Mutch; Paul J Goodfellow; David Scott Miller ; Tim H M Huang;
PUBLISHED: 2009, SOURCE: Cancer Research, VOLUME: 69, ISSUE: 23
INDEXED IN: Scopus CrossRef: 219
IN MY: ORCID
183
TITLE: Pharmacotherapy of endometrial cancer
AUTHORS: Nicanor I Barrena Medel; Sharmilee Bansal; David Scott Miller ; Jason D Wright; Thomas J Herzog;
PUBLISHED: 2009, SOURCE: Expert Opinion on Pharmacotherapy, VOLUME: 10, ISSUE: 12
INDEXED IN: Scopus CrossRef: 17
IN MY: ORCID
184
TITLE: Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group
AUTHORS: David Scott Miller ; John A Blessing; Carolyn N Krasner; Robert S Mannel; Parviz Hanjani; Michael L Pearl; Steven E Waggoner; Cecelia H Boardman;
PUBLISHED: 2009, SOURCE: Journal of Clinical Oncology, VOLUME: 27, ISSUE: 16
INDEXED IN: Scopus CrossRef: 140
IN MY: ORCID
185
TITLE: Recent progress: Gynecologic oncology group trials in uterine corpus tumors
AUTHORS: Louise P King; David Scott Miller ;
PUBLISHED: 2009, SOURCE: Reviews on Recent Clinical Trials, VOLUME: 4, ISSUE: 2
INDEXED IN: Scopus CrossRef: 1
IN MY: ORCID
186
TITLE: Somatic LKB1 mutations promote cervical cancer progression  Full Text
AUTHORS: Shana N Wingo; Teresa D Gallardo; Esra A Akbay; Mei Chi Liang; Cristina M Contreras; Todd Boren; Takeshi Shimamura; David Scott Miller ; Norman E Sharpless; Nabeel Bardeesy; David J Kwiatkowski; John O Schorge; Kwok Kin Wong; Diego H Castrillon;
PUBLISHED: 2009, SOURCE: PLoS ONE, VOLUME: 4, ISSUE: 4
INDEXED IN: Scopus CrossRef: 211
IN MY: ORCID
187
TITLE: A phase II evaluation of pemetrexed (LY231514, IND #40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the gynecologic oncology group
AUTHORS: David Scott Miller ; Blessing, JA; Krasner, CN; Mannel, RJ;
PUBLISHED: 2008, SOURCE: Journal of Clinical Oncology, VOLUME: 26, ISSUE: 15_suppl
INDEXED IN: CrossRef: 4
IN MY: ORCID
188
TITLE: Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group  Full Text
AUTHORS: David Scott Miller ; John A Blessing; Diane C Bodurka; Albert J Bonebrake; John O Schorge;
PUBLISHED: 2008, SOURCE: Gynecologic Oncology, VOLUME: 110, ISSUE: 1
INDEXED IN: Scopus CrossRef: 47
IN MY: ORCID
189
TITLE: Gynecologic oncology group trials in uterine corpus malignancies: recent progress
AUTHORS: David Scott Miller ; Louise P King;
PUBLISHED: 2008, SOURCE: Journal of Gynecologic Oncology, VOLUME: 19, ISSUE: 4
INDEXED IN: CrossRef: 16
IN MY: ORCID
190
TITLE: Implications of EGFR inhibition in ovarian cancer cell proliferation  Full Text
AUTHORS: Shawna L Bull Phelps; John O Schorge; Michael J Peyton; Hisayuki Shigematsu; Li Lin Xiang; David Scott Miller ; Jayanthi S Lea;
PUBLISHED: 2008, SOURCE: Gynecologic Oncology, VOLUME: 109, ISSUE: 3
INDEXED IN: Scopus CrossRef: 30
IN MY: ORCID
Page 19 of 30. Total results: 293.

A place for researchers and their institutions

Useful Links

Get Help

© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service